Latest Restructuring News

Mach7 Technologies reported a 17.4% revenue drop to $27.9 million and a 44% increase in net loss to $8.9 million for FY26, driven by a strategic transition to a subscription model and cost base restructuring.

NobleOak Life delivered robust FY26 results with in-force premiums climbing 18% to $549.2 million and underlying NPAT up 15%, driven by strong market share gains and operational efficiency.

Locate Technologies (NZX: LOC) posted a NZD 3.53 million loss for FY2026 despite 7.8% revenue growth, facing refinancing uncertainty on a major debt facility due in November.

Air New Zealand reported a $242 million net loss after tax for FY2026, hit by soaring fuel costs linked to the Middle East conflict and persistent engine issues. The airline unveiled a new strategy aiming for operational resilience and targeted growth amid ongoing cost pressures.

Dubber Corporation Limited (ASX:DUB) posted a 17% revenue drop in FY26 to $35.1 million, mainly due to a major contract loss in Europe, but narrowed its net loss by 78% excluding impairments and achieved cash flow breakeven in H2.

Alfabs Australia delivered an 11% revenue increase and improved free cash flow in FY26, progressing its debt restructuring and setting the stage for dividend reinstatement.

NTAW Holdings reported a 15.7% revenue drop to $445.3 million in FY2026 but improved net losses and operating EBITDA amid a strategic reset. The company divested its South African stake and plans asset sales as it targets modest growth in FY2027.

Solution Dynamics Limited reported an 85% drop in net profit for FY2026 to NZD 0.38 million, hit by a major contract loss and investment in its new AI-driven dental marketing platform, nGAGE.

Sports Entertainment Group (ASX:SEG) posted a 39% revenue jump and 73% underlying EBITDA growth in FY26, offset by a 93% net profit decline due to tax and one-off impacts. The company is poised for growth with key acquisitions including MediaWorks NZ and the GIANTS Netball license.

Prime Financial Group Ltd grew revenue by 22% to $60.5 million in FY26, driven by acquisitions and core business expansion. However, net profit after tax fell 15%, impacted by a higher tax rate and elevated operating costs.

IVE Group posted a mixed FY26 with a 1.8% revenue decline but underlying profit growth, strategic acquisitions, and notable progress in AI commercialization and climate disclosures.

Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) are in early talks about merging to form a larger infectious disease diagnostics entity, combining rapid pathogen detection with microbiome profiling. The proposed group would have FY2026 pro forma revenue of around A$29 million and a stronger financial footing.